Ovid Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Ovid Therapeutics (Nasdaq: OVID) announced that management will participate in two June 2026 investor conferences focused on neurology.

Events include the Oppenheimer CNS & Neuro-Muscular Summit on June 10 at 3:45 p.m. and the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15, with live and archived webcasts via its investor website.

News Market Reaction – OVID

+3.77%

8 alerts

+3.77% Session close to close

$470.33M Market Cap

0.1x Rel. Volume

In the Jun 4 session, OVID gained 3.77%, reflecting a moderate positive market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company’s management will participate in two upcoming investor conferences:

• Oppenheimer CNS & Neuro-Muscular Summit – Wednesday, June 10 at 3:45 pm ET
• H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference – Monday, June 15
  

A webcast of the presentations can be accessed through the Events & Presentations section of the company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation for approximately 30 days.

About Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to pioneering better, gentler medicines for the brain. The Company discovers and develops differentiated, small molecule medicines for neurological and neuropsychiatric disorders with significant unmet need. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant focal onset seizures (FOS) and developmental and epileptic encephalopathies (DEEs), including tuberous sclerosis complex (TSC) associated seizures and infantile spasms (IS); and OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit www.ovidrx.com.

Contact

Investor Relations & Media
Victoria Fort
VFort@ovidrx.com
202.361.0445

FAQ

When will Ovid Therapeutics (NASDAQ: OVID) present at the Oppenheimer CNS & Neuro-Muscular Summit 2026?

Ovid Therapeutics will present at the Oppenheimer CNS & Neuro-Muscular Summit on Wednesday, June 10, 2026 at 3:45 p.m. According to the company, a live webcast will be available via its investor relations website.

What is the date of Ovid Therapeutics' presentation at the H.C. Wainwright Neuro Perspectives Conference 2026?

Ovid Therapeutics is scheduled to participate in the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on Monday, June 15, 2026. According to the company, investors can access the session by webcast through its investor website.

How can investors access the Ovid Therapeutics (OVID) June 2026 conference webcasts?

Investors can access Ovid Therapeutics' June 2026 conference webcasts via the Events & Presentations section of investors.ovidrx.com. According to the company, both live streams and archived replays will be available.

Will replays of Ovid Therapeutics' June 2026 investor conference presentations be available?

Yes, replays will be available. Ovid Therapeutics plans to host an archived webcast replay of the June 2026 presentations on its website. According to the company, access will remain for approximately 30 days after the live events.

What topics might Ovid Therapeutics cover at the June 2026 CNS and neuro investor conferences?

Ovid Therapeutics is joining conferences focused on CNS and neuro-muscular disorders, suggesting emphasis on its neurology pipeline. According to the company, these events allow management to discuss its approach to developing gentler medicines for brain disorders with unmet needs.